Røssevold, Andreas Hagen http://orcid.org/0000-0002-7212-0111
Andresen, Nikolai Kragøe http://orcid.org/0000-0001-9386-1368
Bjerre, Christina Annette http://orcid.org/0000-0003-0530-8090
Gilje, Bjørnar
Jakobsen, Erik Hugger
Raj, Sunil Xavier
Falk, Ragnhild Sørum
Russnes, Hege Giercksky
Jahr, Thea
Mathiesen, Randi Ruud
Lømo, Jon
Garred, Øystein
Chauhan, Sudhir Kumar
Lereim, Ragnhild Reehorst
Dunn, Claire
Naume, Bjørn
Kyte, Jon Amund http://orcid.org/0000-0002-2854-3694
Funding for this research was provided by:
Ministry of Health and Care Services | Helse Sør-Øst RHF (2017100, 2017122)
Kreftforeningen (182632, 214972)
Hoffman-La Roche, Basel
Article History
Received: 17 October 2022
Accepted: 8 November 2022
First Online: 8 December 2022
Competing interests
: J.A.K. has, in the last 3 years, received research support from Bristol Myers Squibb, F. Hoffmann-La Roche, NanoString and NEC OncoImmunity and has previously received advisory board/lecture honoraria from pharmaceutical companies, including Roche. B.G. has, in the last 3 years, received honoraria for advisory boards from Eli Lilly, Gilead Sciences, Daiichi Sankyo, Roche and Pierre Fabre. S.X.R. and J.L. have received lecture honoraria from Pfizer, Novartis and AstraZeneca. C.B. has received travel grants or advisory board/consultant honoraria from Eli Lilly, Pfizer, AstraZeneca, Gilead Sciences, MSD and Daiichi Sankyo. All other authors declare no competing interests.